Coya Therapeutics (COYA) Stock Price, News & Analysis

Company Overview

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $5.65 to $5.94
• 50-Day Range: $4.93 to $6.89
• 52-Week Range: $4.65 to $10.24
• Volume: 22,099 shs
• Average Volume: 72,801 shs
• Market Capitalization: $94.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.00
• Consensus Rating: Buy

Coya Therapeutics Stock Analysis - MarketRank™

Coya Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 635th out of 915 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Coya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Coya Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.47) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Coya Therapeutics is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coya Therapeutics is -8.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coya Therapeutics has a P/B Ratio of 2.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.90% of the float of Coya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coya Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coya Therapeutics has recently decreased by 12.01%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coya Therapeutics does not currently pay a dividend.

Dividend Growth

Coya Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.90% of the float of Coya Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coya Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Coya Therapeutics has recently decreased by 12.01%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.46

News Sentiment

Coya Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Coya Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for COYA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coya Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.80% of the stock of Coya Therapeutics is held by insiders.

Percentage Held by Institutions

Only 39.75% of the stock of Coya Therapeutics is held by institutions.

COYA Stock Analysis - Frequently Asked Questions

How have COYA shares performed this year?

Coya Therapeutics' stock was trading at $5.73 on January 1st, 2025. Since then, COYA shares have decreased by 1.0% and is now trading at $5.67.
View the best growth stocks for 2025 here.

How were Coya Therapeutics' earnings last quarter?

Coya Therapeutics, Inc. (NASDAQ:COYA) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.44) EPS for the quarter, hitting analysts' consensus estimates of ($0.44). The business earned $257.88 million during the quarter, compared to analyst estimates of $2.63 million.

When did Coya Therapeutics IPO?

Coya Therapeutics (COYA) raised $15 million in an initial public offering (IPO) on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share.

Who are Coya Therapeutics' major shareholders?

Top institutional shareholders of Coya Therapeutics include AIGH Capital Management LLC (7.08%), CM Management LLC (1.20%), Dauntless Investment Group LLC (1.00%) and Jane Street Group LLC (0.16%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman.
View institutional ownership trends.

How do I buy shares of Coya Therapeutics?

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Coya Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COYA
• CIK: 1835022
• Web: www.coyatherapeutics.com
• Phone: 800-587-8170
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $17.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +199.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,990,000.00
• Net Margins: N/A
• Pretax Margin: -104.42%
• Return on Equity: -31.63%
• Return on Assets: -27.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.31
• Quick Ratio: 15.31

Sales & Book Value

• Annual Sales: $3.69 million
• Price / Sales: 25.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 2.30

Miscellaneous

• Outstanding Shares: 16,725,000
• Free Float: 14,702,000
• Market Cap: $94.83 million
• Optionable: Not Optionable
• Beta: 0.49